LY-487,379

LY-487,379 is a drug that acts as a positive allosteric modulator at the metabotropic glutamate receptor subtype 2 (mGluR2), which is found in the central nervous system. It was developed by Eli Lilly and Company and has been researched for its potential use in the treatment of schizophrenia and anxiety disorders.

Pharmacology

LY-487,379 is a positive allosteric modulator of the mGluR2 receptor. This means it enhances the activity of the receptor, but does not activate it directly. Instead, it increases the receptor's response to its natural ligand, glutamate. This modulation of glutamate activity may have therapeutic benefits in conditions where glutamate function is disrupted, such as schizophrenia and anxiety disorders.

Clinical Trials

LY-487,379 has undergone Phase I clinical trials for safety and tolerability in healthy volunteers. The results suggested that the drug was well-tolerated with no serious adverse events reported. However, further clinical development of LY-487,379 has not been publicly announced.

Potential Therapeutic Uses

The modulation of mGluR2 activity by LY-487,379 has potential therapeutic implications for several neuropsychiatric disorders. Preclinical studies have suggested that mGluR2 positive allosteric modulators may be beneficial in the treatment of schizophrenia, as they can reduce psychotic symptoms without the side effects associated with current antipsychotic medications. Similarly, they may also be useful in the treatment of anxiety disorders, as mGluR2 has been implicated in the regulation of anxiety-like behaviors.

See Also

• Metabotropic glutamate receptor
• Positive allosteric modulator
• Schizophrenia
• Anxiety disorders

‎